Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
clinical trials
life sciences
national blog main
national top stories
new york blog main
san diego blog main
akcea therapeutics
anylam pharmaceuticals
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
biotech
bluebird bio
boston
cardiomyopathy
drugs
duchenne muscular dystrophy
dyne therapeutics
facioscapulohumeral muscular dystrophy
gene therapy
inotersen
intellectual property law
joshua brumm
kaleido biosciences
monopoly (economics)
muscular dystrophy
myotonic dystrophy type 1
neuropathy
new york
new york top stories
onpattro
patent law
patisiran
pfizer
public records
rare disease drugs
romesh subramanian
What
ago
3
×
genetic
3
×
drug
medicines
rare
akcea
alnylam
ambitious
amyloidosis
announced
approved
attr
available
battle
biotechs
blueprint
build
cancer
considering
controversial
create
data
debilitating
disease
diseases
dyne
early
expected
experimental
eyes
fda
following
genomes
having
human
humans
immune
ipo
ipos
long
Language
unset
Current search:
genetic
×
ago
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@theverge.com
7 years ago
How scientists could patent the genetic blueprint for a human